Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 58 clinical trials
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

This phase III trial studies how well nivolumab and ipilimumab works with or without local consolidation therapy in treating patients with stage IV non-small cell lung cancer. Immunotherapy with

lung adenocarcinoma
nivolumab
neutrophil count
crizotinib
lung carcinoma
  • 53 views
  • 19 Jun, 2022
  • 5 locations
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

This phase Ib trial studies the side effects and best dose of telaglenastat hydrochloride when given together with osimertinib in treating patients with stage IV non-small cell lung cancer and a

neutrophil count
gefitinib
brain imaging
metastasis
tyrosine
  • 10 views
  • 01 Jul, 2022
  • 5 locations
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

This study is a multi-center, Phase I/II, single arm trial to assess the safety and efficacy of the combination of oral rucaparib plus intravenous pembrolizumab as maintenance therapy in patients with stage IV non-squamous non-small cell lung cancer (NSCLC) without progressive disease (PD), as confirmed on CT scans, after induction …

pembrolizumab
lymphoma
cancer
carboplatin
progressive disease
  • 8 views
  • 04 Feb, 2022
  • 3 locations
Ruxolitinib for Cancer Cachexia

To assess toxicity with use of Ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in cachexia and anorexia.

  • 0 views
  • 14 May, 2022
  • 1 location
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

This phase Ib/II trial studies the side effects and best dose of trastuzumab and necitumumab together with osimertinib, and to see how well they work for the treatment of stage IV non-small cell

  • 0 views
  • 12 Mar, 2022
  • 1 location
Sintilimab Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

This is a single-arm, prospective, exploratory clinical study aiming to evaluate the efficacy and safety profile of sintilimab combined with anlotinib hydrochloride and platinum-containing dual-agent chemotherapy regimens in advanced or metastatic NSCLC as first-line treatment. Totally 40 patients with negative driver genes (20 patients of squamous cell carcinoma, 20 patients …

  • 0 views
  • 18 Aug, 2021
  • 1 location
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative

This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) vs. usual treatment alone in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (advanced) or has spread to other places in the body …

  • 0 views
  • 27 Jun, 2022
  • 32 locations
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma

patients with unresectable stage III/IV cutaneous melanoma or with stage IV NSCLC (PDL1 50%). The PEV vaccines will be prepared on an individual basis, following a tumor biopsy performed at the time of

lung cancer
RET
EGFR
pembrolizumab
malignant melanoma of skin
  • 0 views
  • 18 Sep, 2021
  • 12 locations
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC

The options for patients with locally advanced non-small cell lung cancer (NSCLC) who are not candidates for a standard definitive chemoradiotherapy regime are meagre. These are patients who are not fit for a chemoradiotherapy schedule of 66 Gy in 2 Gy fractions due to either tumour extent, resulting in excessive …

  • 0 views
  • 22 Jan, 2021
  • 1 location
Study of Crizotinib for ROS1 and MET Activated Lung Cancer

This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective …

crizotinib
measurable disease
squamous non-small cell lung cancer
ROS1
cancer
  • 0 views
  • 18 Dec, 2021
  • 1 location